jounce.png
Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors
23 janv. 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...